WITHDRAWN: CAR T cells : indications actuelles en pédiatrie et perspectives de développement

Ramos, 2016, CAR-T Cell Therapy for Lymphoma, Annu Rev Med, 67, 165, 10.1146/annurev-med-051914-021702

Wang, 2015, Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies, Cancer Gene Ther, 22, 85, 10.1038/cgt.2014.81

Carpenito, 2009, Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains, Proc Natl Acad Sci U S A, 106, 3360, 10.1073/pnas.0813101106

Savoldo, 2011, CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients, J Clin Invest, 121, 1822, 10.1172/JCI46110

van der Stegen, 2015, The pharmacology of second-generation chimeric antigen receptors, Nat Rev Drug Discov, 14, 499, 10.1038/nrd4597

Pegram, 2015, IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia, Leukemia, 29, 415, 10.1038/leu.2014.215

Turtle, 2015, Addition of fludarabine to cyclophosphamide lymphodepletion improves in vivo expansion of CD19 chimeric antigen receptor-modified T cells and clinical outcome in adults with B cell Acute lymphoblastic leukemia, Blood, 126, 3773, 10.1182/blood.V126.23.3773.3773

Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N Engl J Med, 368, 1509, 10.1056/NEJMoa1215134

Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet Lond Engl, 385, 517, 10.1016/S0140-6736(14)61403-3

Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222

Maude, 2018, Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia, N Engl J Med, 378, 439, 10.1056/NEJMoa1709866

Neelapu, 2017, Axicabtagene Ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447

Jacoby, 2015, Lineage switch as a relapse mechanism of pre-B acute lymphoblastic leukemia following CD19 CAR, Blood, 126, 2524, 10.1182/blood.V126.23.2524.2524

Sotillo, 2015, Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy, Cancer Discov, 5, 1282, 10.1158/2159-8290.CD-15-1020

Haso, 2013, Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia, Blood, 121, 1165, 10.1182/blood-2012-06-438002

Fry, 2018, CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy, Nat Med, 24, 20, 10.1038/nm.4441

Mamonkin, 2015, A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies, Blood, 126, 983, 10.1182/blood-2015-02-629527

Kenderian, 2015, CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia, Leukemia, 29, 1637, 10.1038/leu.2015.52

Cartellieri, 2016, Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts, Blood Cancer J, 6, e458, 10.1038/bcj.2016.61

Sallman, 2018, NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient, Haematologica, 10.3324/haematol.2017.186742

Ramos, 2017, Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes, J Clin Invest, 127, 3462, 10.1172/JCI94306

Castellarin, 2018, Driving cars to the clinic for solid tumors, Gene Ther, 10.1038/s41434-018-0007-x

Richman, 2018, High-affinity GD2-Specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model, Cancer Immunol Res, 6, 36, 10.1158/2326-6066.CIR-17-0211

Majzner, 2017, Harnessing the immunotherapy revolution for the treatment of childhood cancers, Cancer Cell, 31, 476, 10.1016/j.ccell.2017.03.002

Migliorini, 2018, CAR T-Cell therapies in glioblastoma: a first look, Clin Cancer Res, 24, 535, 10.1158/1078-0432.CCR-17-2871

Ahmed, 2017, HER2-Specific Chimeric Antigen receptor-modified virus-specific T Cells for progressive glioblastoma: a phase 1 dose-escalation trial, JAMA Oncol, 3, 1094, 10.1001/jamaoncol.2017.0184

Brown, 2016, Regression of glioblastoma after chimeric antigen receptor T-Cell therapy, N Engl J Med, 375, 2561, 10.1056/NEJMoa1610497

Ahmed, 2015, Human Epidermal Growth Factor Receptor 2 (HER2) – Specific chimeric antigen receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma, J Clin Oncol, 33, 1688, 10.1200/JCO.2014.58.0225

Qasim, 2017, Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells, Sci Transl Med, 9, 374, 10.1126/scitranslmed.aaj2013

Roybal, 2016, Precision tumor recognition by T Cells with combinatorial antigen-sensing circuits, Cell, 164, 770, 10.1016/j.cell.2016.01.011

Biondi, 2017, Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia, J Autoimmun, 85, 141, 10.1016/j.jaut.2017.08.003

Ruella, 2016, Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies, J Clin Invest, 126, 3814, 10.1172/JCI87366

Fraietta, 2016, Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia, Blood, 127, 1117, 10.1182/blood-2015-11-679134

Maude, 2017, The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL), J Clin Oncol, 35, 103, 10.1200/JCO.2017.35.15_suppl.103

June, 2018, CAR T cell immunotherapy for human cancer, Science, 359, 1361, 10.1126/science.aar6711

Di Stasi, 2011, Inducible apoptosis as a safety switch for adoptive cell therapy, N Engl J Med, 365, 3363, 10.1056/NEJMoa1106152

Mehta, 2018, Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer, Front Immunol, 9, 283, 10.3389/fimmu.2018.00283

Kebriaei, 2016, Phase I trials using sleeping beauty to generate CD19-specific CAR T cells, J Clin Invest, 126, 3363, 10.1172/JCI86721

Hudecek, 2016, Minicircle-based engineering of chimeric antigen receptor (CAR) T Cells, Recent Results Cancer Res, 209, 37, 10.1007/978-3-319-42934-2_3